Neuronetics, Inc.

American company

STIM Nasdaq ISIN US64131A1051 SEC CIK 1227636 LEI 549300T0911ILTTG7P06
Follow Neuronetics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $42M +12.5% vs same quarter last year
Net income −$1.7M +81.3% vs same quarter last year
EPS, diluted −$0.02 +84.6% vs same quarter last year
Operating cash flow $1.2M +257.7% vs same quarter last year
Revenue by quarter
$22.5M
$32M
$38.1M
$37.3M
$41.8M
$34.5M
$41.6M
$42M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100M$150MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$149.2M−$39M
FY24$74.9M−$43.7M
FY23$71.3M−$30.2M
FY22$65.2M−$37.2M
FY21$55.3M−$31.2M
FY20$49.2M−$27.5M
FY19$62.7M−$29M
FY18$52.8M−$24.1M
FY17$40.4M−$16.1M
FY16$34.2M−$11.2M
FY15--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2548.5%−21.1%−26.1%
FY2472.3%−46.2%−58.4%
FY2372.5%−42.8%−42.3%
FY2276.3%−53.8%−57%
FY2178.9%−49.8%−56.4%
FY2076.5%−45.3%−55.7%
FY1975.4%−43%−46.4%
FY1876.4%−37.6%−45.7%
FY1776.2%−33.7%−39.7%
FY1680.7%−27.3%−32.8%
FY15---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$21.2M
FY24−$32.5M
FY23−$34.4M
FY22−$34M
FY21−$30.3M
FY20−$29.1M
FY19−$31.3M
FY18−$21.6M
FY17−$11.7M
FY16−$8.9M
FY15-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Neuronetics
  • Healthcare median
−100%−75%−50%−25%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearNeuroneticsHealthcare median
FY25−26.1%−30.6%
FY24−58.4%−47%
FY23−42.3%−58%
FY22−57%−80.4%
FY21−56.4%−71.8%
FY20−55.7%−62.2%
FY19−46.4%−46.2%
FY18−45.7%−49.6%
FY17−39.7%−45.9%
FY16−32.8%−36%
FY15-−37.8%